Corcept Therapeutics | CORT - Debt


Corcept Therapeutics reported $6.6M in Debt for its fiscal quarter ending in June of 2025.





Debt Change Date
Acadia Pharmaceuticals USD 56.29M 1.36M Jun/2025
Alaunos Therapeutics USD 10.99M 5.78M Mar/2023
ANI Pharmaceuticals USD 620.31M 1.25M Sep/2025
Ardelyx USD 207.61M 968K Sep/2025
Aurora Cannabis CAD 100.34M 1.29M Sep/2025
BioMarin Pharmaceutical USD 603.87M 8.22M Jun/2025
Bristol-Myers Squibb USD 50.93B 1.22B Jun/2025
Canopy Growth CAD 259.33M 68.47M Sep/2025
Corcept Therapeutics USD 6.6M 2.03M Jun/2025
Eli Lilly USD 42.51B 2.6B Sep/2025
J&J USD 45.8B 4.97B Sep/2025
Knight Therapeutics CAD 106.24M 1.5M Sep/2025
Merck USD 41.37B 5.97B Sep/2025
Novartis USD 32.64B 1.37B Jun/2025
Novartis USD 32.02B 615M Sep/2025
Pacira USD 376.72M 203.77M Sep/2025
Pfizer USD 60.85B 78M Sep/2025
Supernus Pharmaceuticals USD 31.77M 531K Jun/2025
TG Therapeutics USD 245.34M 8.38M Sep/2025